Lupin has informed that it enclosed a Press Release as regards, the Company has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina.
The above information is a part of company’s filings submitted to BSE.